Thanks all. That makes sense. As I said, I can see (and believe in) the potential of SAR. I suppose my question should have been - why are we still at such a low share price with everything in the pipeline ??????. I’ve been holding here since 0.6p many years ago so happy to wait a while longer.
First things first - a huge thanks (again) for all those posting such quality analysis on this board.
Could someone please explain the logic on predictions for TO price for SAR? Most of thé TO prices I have seen for other shares recently seem to be below a 50% premium to the last closing share price. How/why might this be different for SAR? I can’t get my head round it.
Many thanks.
Hi there Mediman - welcome to the board! (and Xviolet)
I have to ask - in your post Saturday 11:04 you mentioned "The HNWI coming on board this year said to me that nothing will be trundling along now, this is the time, right now."
Was this just a turn of phrase or do you actually know who one of the HNWIs is? We've all been doing so much speculation on identities - it would be great if you have actual details :-)
Happy investing!
This is fantastic!! The rise recently has been great - and IMO related to the potential for SAR re Covid. So this provides a really timely reminder to everyone that this is a multi-pronged opportunity - definitely (continuing) onwards and upwards!!!
The WHO has just approved tocilizumab and sarilumab to treat the impact of Covid, based on the following research - https://jamanetwork.com/journals/jama/fullarticle/2781880, which noted that « Excessive systemic inflammation and raised IL-6 levels resulting from dysregulated host immune responses are associated with adverse clinical outcomes in patients hospitalized with COVID-19.This led to the design of several randomized clinical trials assessing the efficacy of IL-6 antagonists in patients with COVID-19. The IL-6 antagonists commonly investigated were monoclonal antibodies that bind either to membrane-bound and soluble IL-6 receptors (eg, tocilizumab and sarilumab) or directly to IL-6 (eg, siltuximab).
Whilst Tocilizumab and sarilumab are corticosteroids, does this sound to others like they are also targeting the cytokines storm like SAR?
Cobradan - reference to your post: "Knob and nob come to mind take your pick especially if the hat fits and assuming you can read if you read back you will see there is a thread." I am not sure what you are trying to achieve with your post, or indeed to whom it is directed. You may not have meant it to come across as such, however, I read it as a sniping comment towards myself. I value the maturity of many of the posters on this board, and I would encourage all of us to keep exchanges civil.
People have come into this share at different times. Some are sitting on huge profits, some less so. Some have experienced significant swings in their portfolio holdings previously, others less. Some are looking at this purely from a financial perspective, others because they have experience of the dreadful diseases that Sareum is looking to tackle. It would benefit us all to stay polite and benefit from the different perspectives that all can bring. Some are LTHs, others have experience from trading. This is not about trying to have only positive posts. There is nothing wrong with challenging assumptions - indeed that is a real benefit, but it should be done with respect.
Thoth - thanks so much for that repost. As you can see from the tardiness in my reply, I've just been going through it. I will share it also with the security team at my office. It's really useful!
Thanks Caribbean Pirate - good observations. It has been really insightful seeing the difficult approaches to managing the pandemic (I'm in Switzerland, but also very aware of France due to its proximity to where I live - and its vital role in providing affordable food shopping in comparison!! Fingers crossed I will have less of a concern in that area soon........ :-))
Thanks Thoth, this is really useful. As a % it has indeed increased significantly, although as actual numbers, I wonder if this has changed at all for the youth (i.e. their % is going up simply because there are far fewer oldies going to hospital because of vaccinations).
The article that I shared also suggested that the youth are getting immunity through getting Covid, and the older generations through vaccinations. I don't live in the UK, so difficult to have my finger on the pulse of what reality is there, so I cannot comment as to how accurate this analysis is.
Thanks again for the link!
Hi all,
This is really encouraging to see the price continue its steady trajectory. I will admit that I was wondering how things would be this morning after reading a couple of articles in the UK press this weekend going on about Johnson's announcement due today and how much vaccinations had managed to cut the flow into hospitals. https://www.thetimes.co.uk/article/delta-variant-and-the-third-wave-covid-keeps-changing-but-we-can-deal-with-it-5j2pcq693 (not a free article though I think). The sub-heading is "As cases rise but admissions stay low, experts are daring to ask if this is as bad as it is going to get, writes Tom Whipple"
I couldn't see any of Thoth's fears mentioned or even hinted at re the young getting a bad reaction due to cytokine storms and thus (I don't mean this in a callous way so please excuse my clumsy phrasing) creating more of a market for SAR. Can anyone share if this is something that is being discussed more mainstream?
And just to caveat in case someone attributes an intention to this that is not there - I am very grateful / love Thoth's research! I'm a LTH (bought in 2014).
Hi all.
Great RNS! A question to the more knowledgeable- does anyone know if SAR could get admitted to AGILE at any time, or are there set admission dates (e.g. when a committee meets to take decisions?
Many thanks and GLA
Hi all,
There has been a bit of talk on this board on how vaccines are not the silver bullet, and the importance of having a number of different avenues to tackle Covid, including SAR's potential contribution to reducing the cytokine storm. This document from the Swiss Covid science task force provides a useful/readable summary of the projected duration of protection from vaccines - https://sciencetaskforce.ch/en/policy-brief/protection-duration-after-vaccination-or-infection/. I've not seen anything else on this matter, so hence sharing.
Hi all,
SAR has received much more attention and the share price has been much more volatile in the past few days. How much is this due to the fact that in addition to us LTHs, who have little impact on the price because we are sitting tight (beyond a few top slices that some have spoken about), there are now traders piling in? Traders trade both directions at all times, as their decisions are driven by when they last bought/sold (and where they think price is going), so does this not automatically create greater volatility? In which case, it's just up to us to put on the big girl/boy pants and ride out the swings?
RV84 - go to the top of the chat and there is the menu bar that has regular share chat, premium share chat and then filters. Click on that and type in those you want to filter.
I did filter some yesterday - and what surprised me most was that the majority had premium membership. What's that all about??
This journey is amazing, especially in the last few months, and I really want to say a HUGE thanks to all the knowledgeable posters on this board! I know the price goes up and down, so it may be a little while longer before it is breached....... but I am just 5% off reaching a 1,000 % increase on my investment!!!
My biggest challenge is keeping up with my day job and not constantly checking either my share account app or this board!! :-)
GLA and thanks again.
That is three of us stung by Xcite and the others coming out from I am guessing the same broker. I'm not up at the same levels as you guys in terms of numbers of SAR shares (just 710k) but enough to make a difference. GLA.